Metropolis Healthcare profit and loss

Latest FY26
Revenue
₹1,646cr+23.6% on FY25
EBITDA
₹401cr+32.3% on FY25
Net profit
₹191cr+31.4% on FY25
EPS
₹9.19−67.5% on FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
1,7101,6461,3311,2081,148
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
23.225.615.19.115.2
1,7331,6711,3461,2171,163
Expenses
333325269243253
392377314276253
25.524.518.622.526.8
13513410994.589.2
563543446407354
1,4491,4031,1551,042976
422401303283288
287267194188199
Profit
285268191175188
−9.0−9.00.00.00.0
276259191175188
77.173.748.649.751.3
−4.2−5.7−3.3−3.4−7.2
72.868.045.346.244.1
203191146128143
203191146128143
9.84.8−0.3−0.8−0.3
213196145128143
202190145128143
1.21.20.50.60.5
Per share
₹23.35₹9.19₹28.29₹24.95₹27.91
₹23.26₹9.19₹28.15₹24.87₹27.81
Other comprehensive income — detail
9.84.8−0.3——
—0.4——−2.2
−0.50.01.6——
———1.7−0.6
—0.0——1.3
−8.8−4.4−1.3——
———−0.80.0
211195145127143
1.21.20.50.60.5
Per share — as-filed variants
₹23.35₹9.19₹28.29₹24.95₹27.91
₹23.26₹9.19₹28.15₹24.87₹27.81
Derived — gross profit (revenue − materials − purchases − Δ inventories)
1,3771,3211,063965895
80.6%80.3%79.8%79.9%77.9%
Adjusted (ex-exceptional items) — derived
285268191175188
−9.0−9.00.00.00.0
209198146128143
₹24.11₹9.51₹28.29₹24.95₹27.91
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

METROPOLIS₹553.85

Metropolis Healthcare Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersLALPATHLABVIJAYATHYROCAREMARKSANSPARKHOSPSJLHLRUBICONHCGMcap ₹11,483 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations1,148.21,207.71,331.21,645.81,710.0
Other Income15.29.115.125.623.2
Total Income1,163.41,216.81,346.31,671.41,733.2
Expenses
+ Cost of Materials Consumed253.3242.6268.7324.5332.6
+ Employee Benefit Expense252.7275.8313.7377.4392.1
+ Finance Costs26.822.518.624.525.5
+ Depreciation & Amortisation89.294.5108.7133.7135.3
+ Other Expenses353.9406.8445.8543.1563.1
Total Expenses975.91,042.11,155.51,403.31,448.5
EBITDA288.3282.6303.0400.8422.3
EBIT199.1188.1194.3267.1287.0
Profit
PBT before Exceptional Items187.5174.7190.9268.2284.6
+ Exceptional Items0.00.00.0-9.0-9.0
Pretax Income187.5174.7190.9259.2275.7
+ Current Tax51.349.748.673.777.1
+ Deferred Tax-7.2-3.4-3.3-5.7-4.2
Tax Expense44.146.245.368.072.8
Net Income143.4128.5145.5191.2202.8
+ Net Income — Continuing Ops143.4128.5145.5191.2202.8
+ Other Comprehensive Income-0.3-0.8-0.34.89.8
Total Comprehensive Income143.0127.6145.2196.0212.6
Net Income to Common142.9127.8145.0190.0201.6
Minority Interest0.50.60.51.21.2
Per Share
Basic EPS27.9124.9528.299.1923.35
Diluted EPS27.8124.8728.159.1923.26
Other Comprehensive Income — detail
+ Other Comprehensive Income——-0.34.89.8
+ Items NOT to be Reclassified to P&L-2.2——0.4—
+ Tax on Items NOT to be Reclassified——1.60.0-0.5
+ Tax on Items NOT to be Reclassified — alt tag-0.61.7———
+ Items to be Reclassified to P&L1.3——0.0—
+ Tax on Items to be Reclassified——-1.3-4.4-8.8
+ Tax on Items to be Reclassified — alt tag0.0-0.8———
Comprehensive Income — Owners of Parent142.5127.0144.7194.8211.4
Comprehensive Income — Non-controlling Interests0.50.60.51.21.2
Per Share — as-filed variants
Basic EPS — Continuing Operations27.9124.9528.299.1923.35
Diluted EPS — Continuing Operations27.8124.8728.159.1923.26
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit894.9965.11,062.51,321.31,377.4
Gross Margin %77.9479.9179.8280.2880.55
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)187.5174.7190.9268.2284.6
− Exceptional Items (reconciliation)0.00.00.0-9.0-9.0
Net Income Adj (tax-effected)143.4128.5145.5197.8209.4
EPS Adj27.9124.9528.299.5124.11
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.002.00
Paid Up Equity Capital10.210.210.441.541.5
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.